Evidence map›Paper›PMID 41589579›Full record

ArticleJournal of comparative effectiveness research2026

First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis.

Gordon Lam, Hanke Zheng, Andrew Klink, Vardhaman Patel, Emily Bland, Laetitia N'Dri, Parisa Asgarisabet, Keith Wittstock, Cherrishe Brown-Bickerstaff, Mark Chaballa and 2 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of comparative effectiveness research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gordon LamArthritis & Osteoporosis Consultants of the Carolinas, Atrium Health Wake Forest Baptist, Charlotte, NC 28202, USA.
Hanke ZhengBristol Myers Squibb, Princeton, NJ 08543, USA.
Andrew KlinkCardinal Health, Dublin, OH 43017, USA.
Vardhaman PatelBristol Myers Squibb, Princeton, NJ 08543, USA.
Emily BlandCardinal Health, Dublin, OH 43017, USA.
Laetitia N'DriBristol Myers Squibb, Princeton, NJ 08543, USA.
Parisa AsgarisabetCardinal Health, Dublin, OH 43017, USA.
Keith WittstockBristol Myers Squibb, Princeton, NJ 08543, USA.
Cherrishe Brown-BickerstaffCardinal Health, Dublin, OH 43017, USA.
Mark ChaballaBristol Myers Squibb, Princeton, NJ 08543, USA.
Vadim KhaychukBristol Myers Squibb, Princeton, NJ 08543, USA.
Bruce FeinbergCardinal Health, Dublin, OH 43017, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AbataceptAnti-Citrullinated Protein AntibodiesAntirheumatic AgentsArthritis, RheumatoidTumor Necrosis Factor InhibitorsAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesRheumatoid FactorAbataceptAnti-Citrullinated Protein AntibodiesAntirheumatic AgentsRheumatoid FactorTumor Necrosis Factor Inhibitorsabataceptanticitrullinated protein antibodiesbiologiccomorbiditiesdisease-modifying antirheumatic drugreal-worldrheumatoid arthritisrheumatoid factortumor necrosis factor inhibitor

Identifiers

PMID41589579
PMCPMC12884338

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.